Ipamorelin + CJC-1295
A classic secretagogue blend: a selective GH releaser and a long-acting GHRH analog studied together.
A combination of Ipamorelin (a selective growth hormone secretagogue acting via the ghrelin receptor) and CJC-1295 (a long half-life GHRH analog). It is studied for its synergistic effect on pulsatile GH release: one initiates the pulse and the other extends the signal, without marked elevations in cortisol or prolactin in models.
Benefits studied in research
- Studied for its combined effect on pulsatile growth hormone release.
- Investigated for Ipamorelin's selectivity toward GH secretion without marked elevations in cortisol or prolactin in models.
- Evaluated for the prolonged secretagogue-signal half-life contributed by CJC-1295.
- CJC-1295 studied for producing dose-dependent increases in GH and IGF-1 over several days following a single injection in healthy adults.
Key data
- Composition
- Ipamorelin + CJC-1295 (blend)
- Targets
- Ghrelin receptor · GHRH receptor
- Marker
- Endogenous GH · IGF-1
- Selectivity
- No marked cortisol/prolactin spikes (models)
- Storage
- −20 °C lyophilized · 4 °C reconstituted
Scientific backing
Peer-reviewed publications on the molecule. Research references, not indications for use.
Reconstitution calculator
Adjust the values to plan your protocol. The vial's mg sync with the size you select above.
Calculation tool for laboratory planning (RUO). An insulin U-100 syringe has 100 units = 1 ml. Not a dosing recommendation.
Frequently asked questions
Ipamorelin selectively initiates a GH pulse; CJC-1295 prolongs the GHRH signal. In research they are combined to study a sustained effect on GH and IGF-1.
Tesamorelin acts on GHRH alone; this blend adds the ghrelin-receptor pathway, a different approach to the same final target (endogenous GH).
